[{"from": "human", "value": "Provide a description of this molecule. [C][C][=C][C][=Branch2][Ring1][=Branch1][=N][C][=Branch1][Ring2][=N][Ring1][=Branch1][N][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][Branch1][C][F][F][N][C][=Branch1][C][=O][C][=C][Branch2][Ring1][Ring2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][S][=Branch1][C][=O][=Branch1][C][=O][C][C][O][N][C][C][C][Branch1][Branch1][C][C][Ring1][Ring1][C][C][Ring1][Branch2]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, small-molecule inhibitor of the human kinesin-like protein KIF18A, with potential antineoplastic activity. Upon oral administration, sovilnesib selectively inhibits the activity of KIF18A. This may result in multipolar cell division and inhibit tumor cell proliferation. KIF18A, a mitotic kinesin-8 motor protein, plays an important role in the regulation of chromosome positioning during cell division and is overexpressed in certain cancers. Certain cancer cells with chromosomal instability (CIN) features depend on KIF18A activity for bipolar spindle integrity and cell proliferation."}]